01607nas a2200277   4500000000100000008004100001260001300042653001200055653002400067653002300091653001600114653002900130653002700159653001100186653001200197653001800209653002500227653001600252100001300268700001300281245009500294300001200389490000600401520090800407022001401315       2003                            d  c2003 Dec10aAnimals10aAntigens, Bacterial10aBacterial Vaccines10aBCG Vaccine10aClinical Trials as Topic10aDisease Models, Animal10aHumans10aleprosy10aMycobacterium10aMycobacterium leprae10aVaccination1 aGormus B1 aMeyers W00aUnder-explored experimental topics related to integral mycobacterial vaccines for leprosy.  a791-8040 v23 a<p>Many leprosy vaccine studies have utilized live or killed whole mycobacteria, such as Bacille Calmette-Guérin, Indian Cancer Research Center (ICRC) bacilli and Mycobacterium w either alone or in combination with killed Mycobacterium leprae. For Bacille Calmette-Guérin, the vaccine dose is generally that which gives the largest delayed-type hypersensitivity response with minimal side effects. The doses of other integral mycobacterial vaccines appear to be arbitrarily chosen. Hypotheses governing immunologic responses to complex antigens predict that the doses used may be too high, resulting in protection of some individuals and increasing the susceptibility of other individuals to leprosy. The natural history of an individual's prior exposure to environmental mycobacteria will affect the outcome of protective vaccination using a given dose of mycobacterial vaccine in the individual.</p>  a1476-0584